| Title: | Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients |
| Authors: | Ninkovic, S Purton, LE Harrison, SJ Quach, H |
| Issue Year: | 2024 |
| Publisher | FERRATA STORTI FOUNDATION |
| Series | HAEMATOLOGICA: |
| Abstract | A dysfunctional immune tumor microenvironment facilitates disease progression in multiple myeloma (MM). Using multiplex immunohistochemistry (mIHC), we describe the quantitative and qualitative changes in CD3 + CD8 + cytotoxic T cells and assess their proximity to malignant plasma cells (PC) in patients with monoclonal gammopathy of undetermined significance (MGUS), and newly diagnosed (ND) and relapsed and/or refractory (RR) MM. Formalin-fixed, paraffin -embedded trephine sections from patients with MGUS (N=32), NDMM (N=65), and RRMM (N=59) were sequentially stained for CD138, CD3, CD8, and checkpoint receptors (CPR) Tim -3, Lag -3, and PD -1. The Halo (R) image analysis platform was used for cell segmentation and phenotyping, facilitating enumeration of cytotoxic T cells and analysis of proximity to PC. The percentage of CD8 + cytotoxic T cells in proximity to PC is greater in patients with NDMM than patients with RRMM (at 50 m m distance, 90.8% vs. 81.5%; P =0.038). There is a trend for more CD3 + T cells in MGUS ( P =0.08) but no difference was observed in the prevalence of CD8 + cytotoxic T cells ( P =0.48). Lag -3 is the most common CPR expressed on cytotoxic T cells in myeloma ( P <0.0001), while PD -1 is the most common CPR on CD8 - T cells of patients with MGUS and RRMM. Our study is the first to report on the spatial relationship between T cells and PC using mIHC on FFPE bone marrow trephine sections from patients with PC dyscrasia. The proximity of T cells to PC during early stages of MM, and overexpression of Lag -3, validate the move of immune therapeutic strategies, including T -cell engagers and checkpoint inhibitors, to upfront treatment or in early -line treatment of MM. |
| URI: | https://publications.svi.edu.au/publications/9605 |
| Other Identifiers | 10.3324/haematol.2023.283344 |
| Publication type | Article |